Ionis Pharmaceuticals, Inc. (IONS) — Stock Score Summary

Ionis Pharmaceuticals, Inc. (IONS) has a MoatMap StockRank of 27/100 based on Quality (21/100), Value (35/100), and Momentum (57/100) factor scores. The current signal is SELL. Ionis Pharmaceuticals is a biotech firm focused on RNA-targeted therapeutics. It has a low quality score (21) and high R&D cash burn, failing the Terry Smith lens of a high-ROIC, predictable compounder.

Ionis Pharmaceuticals, Inc. is a leading biotechnology company pioneering RNA-targeted therapeutics, developing a broad pipeline of innovative medicines for severe and rare diseases using its proprietary antisense technology platform. The company possesses a unique and validated antisense technology platform with multiple approved drugs and a robust pipeline, providing a significant competitive advantage through its deep intellectual property portfolio. Ionis is a pioneer and leader in antisense oligonucleotide (ASO) drug discovery, offering a differentiated approach to treating a wide range of genetic and severe diseases.

Key Financial Metrics

Price$74.58
Market Cap$12.8B
P/E (Forward)-120.81
Price/Book25.36
Return on Equity-67.6%
Return on Invested Capital-10.8%
Debt/Equity531.05
Gross Margin10.9%
Operating Margin-47.7%
Revenue Growth87.0%
Free Cash Flow$-808M

Ionis Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Ionis Pharmaceuticals, Inc.’s (IONS) StockRank?
MoatMap’s StockRank for Ionis Pharmaceuticals, Inc. (IONS) is 27/100, with a Sell signal. It is a composite of Quality (21), Value (35), and Momentum (57) factor ranks across MoatMap’s 19,000+ stock universe.
Does Ionis Pharmaceuticals, Inc. have an economic moat?
Ionis Pharmaceuticals, Inc. (IONS) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Ionis Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Ionis Pharmaceuticals, Inc. (IONS) is Sell, based on a StockRank of 27/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Ionis Pharmaceuticals, Inc. in?
Ionis Pharmaceuticals, Inc. (IONS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksIONS deep dive reportAI ChampionsHow we score stocksSense-check another stock